quantum-chemistry

(7)
Company
Creyon Bio
Ai · Health · Enterprise

Creyon Bio

Creyon Bio is a San Diego biotech reinventing how RNA-targeted medicines are designed. Founded in 2019 by former Ionis Pharmaceuticals scientists, the company pairs machine learning with quantum-level molecular modeling in its NucleIQ platform - an AI-Powered Oligo Engineering Engine - to predict the safety, efficacy, and delivery of oligonucleotide-based medicines before they ever reach a lab bench. The goal: replace slow, expensive trial-and-error with computational design rules that make precision therapeutics engineerable 'on demand,' for both rare and common diseases across neuromuscular, CNS, and immunologic areas.

rna-therapeutics · oligonucleotidesRead →
Company
QC Ware Corp.
Ai · Saas · Enterprise

QC Ware Corp.

QC Ware is a Palo Alto-based enterprise software company that builds quantum and quantum-inspired tools for hard scientific problems. Founded in 2014 by veterans of NASA Ames, it started as a hardware-agnostic quantum cloud platform (Forge) and evolved into Promethium, a GPU-accelerated quantum chemistry SaaS that runs density functional theory calculations on molecules up to thousands of atoms, claiming speeds 10 to 100 times faster than legacy tools. The company also runs Q2B, the largest annual practical quantum computing conference, and counts Goldman Sachs, Airbus, BMW and Covestro among its collaborators and investors.

quantum-computing · quantum-chemistryRead →
Legend
Haojun Jia
Founder · Scientist · Executive

Haojun Jia

Haojun Jia is the co-founder and CEO of Deep Principle, an AI-for-science startup building AI scientists that discover new materials and chemical reactions. He hatched the idea while finishing a physical chemistry PhD at MIT, where his research paired high-throughput quantum chemistry with machine learning to design catalysts. Deep Principle's platform - marketed as ReactiveAI and now the agentic tool Agent Mira - fuses deep learning with first-principles physics to compress the time and cost of materials R&D. The company has raised roughly $28 million across two rounds from investors including GL Ventures, Linear Capital, Vertex Ventures, and funds backed by Lenovo and Baidu. Jia was named to the Forbes 30 Under 30 Asia 2025 list in Healthcare & Science.

haojun-jia · jia-haojunRead →
Company
Deep Principle
Ai · Climate · Enterprise

Deep Principle

Deep Principle is an AI-for-Science company spun out of MIT that builds ReactiveAI, a closed-loop R&D platform fusing generative AI, quantum chemistry, and high-throughput experimentation to discover new materials, catalysts, and chemical processes far faster and cheaper than traditional trial-and-error labs. Founded by MIT PhDs Haojun Jia and Chenru Duan, the company targets materials, energy, and pharmaceutical R&D and has reported quantum-chemistry speedups on the order of 20,000x versus conventional DFT.

ai-for-science · ai4sRead →
Company
Fathom Therapeutics
Ai · Health

Fathom Therapeutics

Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.

drug-discovery · ai-drug-designRead →
Legend
Huafeng Xu
Founder · Scientist · Executive

Huafeng Xu

Huafeng Xu is the founder and CEO of Fathom Therapeutics (formerly AtomMap), a New York drug-design company that simulates protein motion at atomic resolution to design small molecules that work inside living cells. A computational chemist with 25+ years and 10,000+ citations, Xu spent 12 years at D. E. Shaw Research building the free-energy and molecular-dynamics methods now standard across pharma, then served as CTO of Silicon Therapeutics and Roivant Discovery before launching his own company. In April 2026 Fathom closed an oversubscribed $47M Series A led by Sutter Hill Ventures to scale its Microcosmos engine.

drug-discovery · computational-chemistryRead →
Legend
Aaron Sisto
Founder · Executive · Investor

Aaron Sisto

Aaron Sisto is the Co-Founder & CEO of Chronicle Studios, a content intelligence platform that uses proprietary agentic AI to help creators launch and scale global IP franchises. A PhD quantum chemist turned deep-tech investor turned entertainment entrepreneur, Sisto blends hard science and pop culture instincts in a company that raised an oversubscribed $11.6M seed round in 2025 backed by Patron and Point72 Ventures. Previously a partner at First Spark Ventures and Director of Engineering at Schmidt Futures, he co-founded Chronicle alongside entertainment veteran Chris deFaria, former president of DreamWorks Animation.

chronicle-studios · aiRead →